These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 12046844)

  • 1. Regulatory issues in cellular therapies.
    Gee AP
    J Cell Biochem Suppl; 2002; 38():104-12. PubMed ID: 12046844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of regulatory policy on the development of somatic cell therapies in the United States.
    Gee AP
    Transpl Immunol; 2002 May; 9(2-4):295-300. PubMed ID: 12180844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. United States Food and Drug Administration Regulation of Gene and Cell Therapies.
    Bailey AM; Arcidiacono J; Benton KA; Taraporewala Z; Winitsky S
    Adv Exp Med Biol; 2015; 871():1-29. PubMed ID: 26374210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current state of U.S. Food and Drug Administration regulation for cellular and gene therapy products: potential cures on the horizon.
    Mendicino M; Fan Y; Griffin D; Gunter KC; Nichols K
    Cytotherapy; 2019 Jul; 21(7):699-724. PubMed ID: 31196820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A decade of marketing approval of gene and cell-based therapies in the United States, European Union and Japan: An evaluation of regulatory decision-making.
    Coppens DGM; de Wilde S; Guchelaar HJ; De Bruin ML; Leufkens HGM; Meij P; Hoekman J
    Cytotherapy; 2018 Jun; 20(6):769-778. PubMed ID: 29730080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A roadmap toward clinical translation of genetically-modified stem cells for treatment of HIV.
    Abou-El-Enein M; Bauer G; Reinke P; Renner M; Schneider CK
    Trends Mol Med; 2014 Nov; 20(11):632-42. PubMed ID: 25262540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulatory considerations for pluripotent stem cell therapies.
    Carpenter MK
    Prog Brain Res; 2017; 230():151-163. PubMed ID: 28552227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Code of Federal Regulations (CFRs): where it all begins.
    Kreuger J; Stengl A; Skalitzky D; Wehmeyer P
    Qual Assur; 1994 Mar; 3(1):82-7. PubMed ID: 7804622
    [No Abstract]   [Full Text] [Related]  

  • 9. Regulatory considerations for the development of autologous induced pluripotent stem cell therapies.
    Carpenter MK; Couture LA
    Regen Med; 2010 Jul; 5(4):569-79. PubMed ID: 20632860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urgent Need for Regulatory Oversight of Human Cells, Tissues, and Cellular and Tissue-Based Products.
    Dickson RP; Dingell DA
    JAMA; 2024 May; 331(20):1703-1704. PubMed ID: 38696201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDA issues guidance on regulation of cell-based products in animals.
    J Am Vet Med Assoc; 2014 Sep; 245(5):474. PubMed ID: 25289407
    [No Abstract]   [Full Text] [Related]  

  • 12. Administrative and research policies required to bring cellular therapies from the research laboratory to the patient's bedside.
    Yim R
    Transfusion; 2005 Oct; 45(4 Suppl):144S-58S. PubMed ID: 16181400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. US Food and Drug Administration international collaborations for cellular therapy product regulation.
    Arcidiacono JA; Blair JW; Benton KA
    Stem Cell Res Ther; 2012 Sep; 3(5):38. PubMed ID: 23021082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulatory issues in cellular therapies.
    Gee AP
    Expert Opin Biol Ther; 2003 Jul; 3(4):537-40. PubMed ID: 12831359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mesenchymal stem-cell therapy in a regulated environment.
    Gee A
    Cytotherapy; 2001; 3(5):397-8. PubMed ID: 11953020
    [No Abstract]   [Full Text] [Related]  

  • 16. Experience of gene therapy in the United Kingdom.
    Nevin NC
    Ann N Y Acad Sci; 1998 Dec; 862():184-7. PubMed ID: 9928223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The little agency that could (act with indifference to constitutional and statutory strictures).
    Noah L
    Cornell Law Rev; 2008 Jul; 93(5):901-26. PubMed ID: 18618963
    [No Abstract]   [Full Text] [Related]  

  • 18. Overview of a quality assurance/quality control compliance program consistent with FDA regulations and policies for somatic cell and gene therapies: a four year experience.
    du Moulin GC; Pitkin Z; Shen YJ; Conti E; Stewart JK; Charles C; Hamilton D
    Cytotechnology; 1994; 15(1-3):365-72. PubMed ID: 7765951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unified agenda of federal regulatory and deregulatory actions--HHS. Semiannual regulatory agenda.
    Fed Regist; 1998 Nov; 63(216 Pt 2):61680-786. PubMed ID: 10187396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality Assessment and Production of Human Cells for Clinical Use.
    Fraser L; Bruce K; Campbell JM; De Sousa PA
    Methods Mol Biol; 2018; 1780():607-629. PubMed ID: 29856038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.